The CCR2 inhibitor PF-04136309 has been shown to improve the survival of pancreatic cancer patients in combination with FOLFIRINOX, improves the chances of survival for individuals diagnosed with pancreatic cancer, demonstrating an improved antitumor response (NCT01413022). Here, CCR2 is linked to pancreatic neoplasm.